The experimentally evolved fluconazole-resistant Clade II isolates of Candidozyma auris exhibit a distinct lipid compositional landscape, highlighting intra-clade sphingolipid heterogeneity
Praveen KumariD, Basharat AliiD, Mohit KumariD, Hans CarolusiD, Celia Lobo Romero, Rudy Vergauwen, Anshu Chauhan, Aswathy NarayananiD, Atanu BanerjeeiD, Naseem Akhtar GauriD, Ashutosh SinghiD, Patrick Van DijckiD, Arunaloke ChakrabartiiD, Shivaprakash Mandya RudramurthyiD, Kaustuv SanyaliD, Rajendra PrasadiD
Abstract
The intrinsic resistance of Candidozyma auris to antifungal drugs poses a major therapeutic challenge, with conventional resistance mechanisms providing only partial explanations. Sphingolipids (SLs), known for their interclade heterogeneity, play a crucial role in antifungal resistance. This study examined the SL landscape in two drug-susceptible clade II isolates, C-line and P-line, from distinct geographical origins, which were experimentally evolved to develop stable fluconazole (FLC) resistance. The progenitors displayed distinct SL profiles, P1 had higher PhytoCer and OHPhytoCer, indicating a more active acidic SL biosynthesis branch, whereas C1 exhibited elevated OHGlcCer, OHCer, and LCBs, reflecting a greater role of the neutral biosynthesis branch. The principal component analysis (PCA) also confirmed distinct segregation of the two progenitors. Upon evolution, P1.1 and C1.1 adaptors showed significant SL alterations. P1.1 exhibited PhytoCer enrichment, while C1.1 showed reduced OHGlcCer alongside increased PhytoCer, dhCer and OHPhytoCer levels. Notably, OHGlcCer remained unchanged in P1.1, whereas LCBs and OHPhytoCer decreased compared to P1. Despite these lineage-specific differences between the progenitors, both evolved replicates exhibited increased PhytoCer as a common denominator like what is also observed in clinical FLC-resistant isolates. These findings highlight intra-clade SL variability and suggest that specific SLs contribute to FLC resistance in C. auris.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 14th percentile
- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The sphingolipid inhibitor myriocin increases susceptibility of Candida auris to amphotericin B
H. Stieber, L. Junghanns, … R. Martin·bioRxiv·Apr 14, 2022
- Microevolution of clade II isolates of Candida auris highlights multifaceted intra-clade heterogeneity in acquiring resistance towards amphotericin B
A. Chauhan, P. Kumar, … R. Prasad·bioRxiv·Sep 20, 2023
- In vitro evolution of caspofungin resistance in Candidozyma auris via FKS1 hotspot I mutations results in moderate fitness trade-offs but no reduction in virulence
Zoe K. Ross, Sakinah Alsayegh, … Alexander Lorenz·Microbiological ResearchPeer-reviewed·Aug 20, 2025
- Short-Term Evolution and Dispersal Patterns of fluconazole-resistance in Candida auris clade III
Irving Cancino‐Muñoz, Juan Vicente Mulet Bayona, … Fernando Gónzález‐Candelas·mBioPeer-reviewed·Dec 27, 2024
- Antifungal Resistance and Adhesin-Mediated Phenotypic Plasticity Among Genomically Diverse Candida auris Clinical Isolates
Tristan Wang, Tao Ma, … Mary Ann Jabra‐Rizk·bioRxiv·Aug 31, 2026
- Genomic diversity across Candida auris clinical isolates shapes rapid development of antifungal resistance in vitro and in vivo
L. S. Burrack, R. T. Todd, … A. Selmecki·bioRxiv·Mar 25, 2022